neovascular age-related macular degeneration

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1773935700011
Cache Key: cqdTagPageBySlug:neovascular-age-related-macular-degeneration
fetchCache[cqdTagPageBySlug:neovascular-age-related-macular-degeneration].expirationTime: falsey
fetchCache[cqdTagPageBySlug:neovascular-age-related-macular-degeneration]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: -912544
-- Key: cqdTagPageBySlug:daniel-ontaneda, seconds remaining: -9128933
-- Key: cqdPostsByTag:cqd-migrated-tag-17439,1,10, seconds remaining: -9128755
-- Key: cqdTagPageBySlug:shane-bobart, seconds remaining: -8915762
-- Key: cqdPostsByTag:cqd-migrated-tag-26264,1,10, seconds remaining: -8915665
-- Key: cqdTagPageBySlug:progression-free-survival, seconds remaining: -7928044
-- Key: cqdPostsByTag:cqd-migrated-tag-23308,1,10, seconds remaining: -7927953
-- Key: cqdTagPageBySlug:temporomandibular-disorders-tmds, seconds remaining: -7470606
-- Key: cqdPostsByTag:cqd-migrated-tag-5420,1,10, seconds remaining: -7470519
-- Key: cqdTagPageBySlug:otoadv1718, seconds remaining: -4717418
-- Key: cqdPostsByTag:cqd-migrated-tag-17802,1,10, seconds remaining: -4717329
-- Key: cqdTagPageBySlug:womens-yir-2021, seconds remaining: -3708456
-- Key: cqdPostsByTag:cqd-migrated-tag-24165,1,10, seconds remaining: -3708351
-- Key: cqdTagPageBySlug:gadolinium-based-contrast-agents, seconds remaining: -1613745
-- Key: cqdPostsByTag:cqd-migrated-tag-23133,1,10, seconds remaining: -1613654
-- Key: cqdTagPageBySlug:stefanie-thomas, seconds remaining: -912544
-- Key: cqdPostsByTag:cqd-migrated-tag-21763,1,10, seconds remaining: -912459
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:neovascular-age-related-macular-degeneration - retrieving from Sanity
CCCache.dataFetchCount: 33
Cache cleanup seconds remaining: 90000

Tag: neovascular age-related macular degeneration

Real-World Results: High-Dose Aflibercept Reduces Macular Fluid, Maintains Vision in nAMD

Faricimab Improves Results for Most Patients on Prior Therapy for nAMD

Exudative Stability Key to Anti-VEGF Outcome in nAMD

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration

Even Brief Delays in Intravitreal Injection Can Cause Vision Loss

Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic

Brolucizumab Delivers Superior Elimination of Retinal Fluid and Possibly Reduced Dosing Frequency than Aflibercept in Two Studies